Rite Aid Reports Same Store Sales for January

CAMP HILL, Pa.--(BUSINESS WIRE)-- Rite Aid Corporation (NYSE: RAD) today announced sales results of its retail pharmacy segment for January.

Monthly Sales

For the four weeks ended Jan. 23, 2016, same store sales decreased 1.4 percent over the prior-year period. January front-end same store sales decreased 1.9 percent. Pharmacy same store sales, which included an approximate 242 basis points negative impact from new generic introductions, decreased 1.2 percent. Prescription count at comparable stores decreased 1.0 percent over the prior-year period.

Total drugstore sales for the four-week period decreased 1.3 percent with sales of $2.000 billion compared to $2.026 billion for the same period last year. Prescription sales accounted for 70.5 percent of drugstore sales, and third party prescription sales represented 97.7 percent of pharmacy sales.

Year-to-Date

Same store sales for the 47-week period ended Jan. 23, 2016 increased 1.5 percent over the prior-year period. Front-end same store sales increased 0.3 percent while pharmacy same store sales increased 2.0 percent. Prescription count at comparable stores increased 0.4 percent over the prior-year period.

Total drugstore sales for the 47 weeks ended Jan. 23, 2016 increased 1.4 percent with sales of $24.119 billion compared to $23.791 billion for the same period last year. Prescription sales represented 69.1 percent of total drugstore sales, and third party prescription sales represented 97.8 percent of pharmacy sales.

Rite Aid is one of the nation’s largest drugstore chains. On Jan. 23, 2016, the company operated 4,558 stores compared to 4,569 stores in the like period a year ago. Information about Rite Aid, including corporate background and press releases, is available through the company’s website at http://www.riteaid.com. Note that all sales data in this release is preliminary, unaudited and subject to revision.

Statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties that are described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in other documents that we file or furnish with the Securities and Exchange Commission, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Rite Aid expressly disclaims any current intention to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160128005707/en/

Rite Aid Corporation
INVESTORS:
Matt Schroeder, 717-214-8867
or [email protected]
or
MEDIA:
Susan Henderson, 717-730-7766

Source: Rite Aid Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Radiopharm reports partial response in RAD204 cancer drug trial
• 4 Greenberg Traurig Attorneys Named to Variety 2026 Music Legal Elite List
• Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases